Security
CELU · Celularity Inc
CELUNASDAQCommon stockCurrentCIK 1752828Updated Sep 24, 2026
Name history
GX Acquisition Corp. · through Jul 19, 2021
CELU price & chart
Loading TradingView…
NASDAQ:CELU on TradingView ↗In the news
Celularity Releases CEO Letter to Shareholders ↗
Recent filings
Other Events
Items 8.01
NT 10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 1.01, 2.03, 5.02, 9.01
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
SCHEDULE 13D/A - filed by Philip & Daniele Barach Family Trust regarding Celularity Inc
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 107,329,000Source | 132,682,000Source | 143,889,000Source | 401,066,000Source |
| Property, Plant and Equipment, NetUSD | 55,797,000Source | 61,600,000Source | 67,828,000Source | 75,655,000Source |
| GoodwillUSD | 7,347,000Source | 7,347,000Source | 7,347,000Source | 119,694,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,756,000Source | 9,248,000Source | 11,001,000Source | 120,994,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,175,000Source | 738,000Source | 227,000Source | 13,966,000Source |
| Inventory, NetUSD | 571,000Source | 5,409,000Source | 5,753,000Source | 5,308,000Source |
| Assets, CurrentUSD | 12,319,000Source | 20,561,000Source | 19,793,000Source | 33,502,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 920,000Source | 857,000Source | 1,695,000Source | 7,262,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,720,000Source | 10,830,000Source | 10,990,000Source | 13,060,000Source |
| Other Assets, NoncurrentUSD | 247,000Source | 270,000Source | 337,000Source | 376,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 145,391,000Source | 123,845,000Source | 102,929,000Source | 202,165,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 19,000Source | 15,000Source |
| Additional Paid in CapitalUSD | 953,418,000Source | 908,523,000Source | 882,732,000Source | 844,373,000Source |
| Retained Earnings (Accumulated Deficit)USD | -991,483,000Source | -899,683,000Source | -841,791,000Source | -645,496,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -5,000Source | — | 9,000Source |
| Stockholders' Equity Attributable to ParentUSD | -38,062,000Source | 8,837,000Source | 40,960,000Source | 198,901,000Source |
| Liabilities and EquityUSD | 107,329,000Source | 132,682,000Source | 143,889,000Source | 401,066,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 80,759,000Source | 53,680,000Source | 67,298,000Source | 62,088,000Source |
| Accounts Payable, CurrentUSD | 26,422,000Source | 23,296,000Source | 14,144,000Source | 5,810,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,898,000Source | 26,548,000Source | 26,177,000Source | 27,985,000Source |
| Deferred Income Tax Liabilities, NetUSD | 12,000Source | 9,000Source | 9,000Source | 9,000Source |
| Other Liabilities, NoncurrentUSD | 266,000Source | 280,000Source | 294,000Source | 321,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 32,574,000Source | 19,842,000Source | 7,580,000Source | 16,402,000Source |
| Deferred Revenue, CurrentUSD | 2,492,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | — | 9,000Source | 9,000Source | 9,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -196,295,000Source | 14,192,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 7,295,000Source | 7,922,000Source | 9,324,000Source | 9,436,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -7,551,000Source | 3,968,000Source | 6,827,000Source | 3,584,000Source |
| Increase (Decrease) in InventoriesUSD | -10,246,000Source | -6,284,000Source | 865,000Source | 16,891,000Source |
| Increase (Decrease) in Accounts PayableUSD | 3,126,000Source | 9,239,000Source | 8,497,000Source | -2,948,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -13,254,000Source | -6,401,000Source | -38,685,000Source | -137,876,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 514,000Source | -4,048,000Source | -5,236,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 161,000Source | 1,048,000Source | 5,236,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 193,000Source | 434,000Source | 101,000Source | 132,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,649,000Source | 6,701,000Source | 24,094,000Source | 119,838,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 5,395,000Source | 814,000Source | -18,639,000Source | -23,274,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 16,372,000Source | 10,977,000Source | 10,163,000Source | 28,802,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,502,000Source | 144,000Source | 1,073,000Source | — |
| Income Taxes Paid, NetUSD | 52,000Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | 1,493,000Source | — | — | — |
| Share-based Payment Arrangement, ExpenseUSD | 10,642,000Source | 11,569,000Source | 15,017,000Source | 15,856,000Source |
| Amortization of Intangible AssetsUSD | 1,493,000Source | 1,753,000Source | 2,193,000Source | 2,193,000Source |
| AssetAcquisitionContingentConsiderationLiabilityUSD | — | 1,413,000Source | — | — |
| DepreciationUSD | 5,803,000Source | 6,169,000Source | 7,131,000Source | 7,243,000Source |
| Gain (Loss) on Sale of DerivativesUSD | 65,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -6,356,000Source | -3,908,000Source | — | — |
| GoodwillUSD | 7,347,000Source | 7,347,000Source | 7,347,000Source | 119,694,000Source |
| Goodwill, Impairment LossUSD | — | — | 112,347,000Source | 3,610,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 2,890,000Source | — | 107,800,000Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -61,308,000Source | -38,358,000Source | -192,287,000Source | — |
| Income Tax Expense (Benefit)USD | 3,000Source | — | 10,000Source | 13,000Source |
| Inventory Write-downUSD | — | — | 6,437,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -91,716,000Source | -57,892,000Source | -196,295,000Source | 14,192,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -91,800,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -30,405,000Source | -19,534,000Source | -3,998,000Source | 39,805,000Source |
| Other Nonoperating Income (Expense)USD | — | 1,560,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | 1,035,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 108,000Source | 58,000Source | 304,000Source | 862,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 26,550,000Source | 54,220,000Source | 22,771,000Source | 17,975,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 51,266,000Source | 58,643,000Source | 50,576,000Source | 66,021,000Source |
| Operating Income (Loss)USD | -61,308,000Source | -38,358,000Source | -192,287,000Source | -25,600,000Source |
| Other Nonoperating Income (Expense)USD | — | 1,560,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -91,713,000Source | -57,892,000Source | -196,285,000Source | 14,205,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | — | 10,000Source | 13,000Source |
| Net Income (Loss) Attributable to ParentUSD | -91,716,000Source | -57,892,000Source | -196,295,000Source | 14,192,000Source |
| Earnings Per Share, BasicUSD per share | -3.59Source | -2.64Source | -11.02Source | 0.1Source |
| Earnings Per Share, DilutedUSD per share | -3.59Source | -2.64Source | -11.02Source | 0.09Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 25,598,586Source | 21,890,518Source | 17,813,044Source | 139,907,029Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 25,598,586Source | 21,890,518Source | 17,813,044Source | 149,830,016Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,493,000Source | 1,753,000Source | 2,193,000Source | 2,193,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | 10,000Source | 13,000Source |
| Goodwill, Impairment LossUSD | — | — | 112,347,000Source | 3,610,000Source |
| Gross ProfitUSD | — | — | 6,755,000Source | -1,690,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -61,308,000Source | -38,358,000Source | -192,287,000Source | — |
| Marketing and Advertising ExpenseUSD | 24,000Source | 23,000Source | 44,000Source | 163,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -91,800,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -30,405,000Source | -19,534,000Source | -3,998,000Source | 39,805,000Source |
| Other ExpensesUSD | 461Source | — | — | — |
| Other General and Administrative ExpenseUSD | 38,804,000Source | 37,703,000Source | — | — |
| Research and Development ExpenseUSD | 15,025,000Source | 17,386,000Source | 30,465,000Source | 78,363,000Source |
Filing attachments
ex99-1.htm · 8-K · 2026-06-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Celularity Appoints Rick Gonzalez as Chief Commercial Officer Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank FLORHAM PARK, NJ, June 3, 2026 (GLOBE NEWSWIRE), Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellu…
Read attachment ↗ex99-2.htm · 8-K · 2026-06-03
EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress. At the same time, we recognize that the broader biotechnology sector, and cellular therapy companies in particular, continue to operate in a highly selective and challenging capital markets environment. Celularity’s leadership…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-21
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Celularity Announces Closing of Transaction with NexGel FLORHAM PARK, N.J., April 21, 2026 - Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity’s biomaterials product portfolio and received an exclusive…
Read attachment ↗